Staccato Prochlorperazine Thorough QT/QTc

Completed · Phase 1 · Has a placebo group

Conditions studied: Cardiotoxicity

In brief

To assess the safety of Staccato Prochlorperazine on cardiac repolarization (QTc interval duration) at 2 dose levels compared to placebo in healthy volunteers.

Key facts

Study ID
NCT00543062
Run by
Alexza Pharmaceuticals, Inc.
People needed
48
Starts
2007-10-01
Expected to finish
2007-12-01
Last updated by the study team
2019-03-11

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.